INS and cancer: Therefore, it is not surprising that a substantial number of observational human studies suggest that treatment with metformin reduces cancer risk as well as cancer mortality [130,131,132,133,134,135], which is in clear contrast to the increased risk for cancer or cancer death associated with the use of exogenous insulin, insulin analog glargine or sulfonylureas [136,137,138].